SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-18-020444
Filing Date
2018-03-27
Accepted
2018-03-27 16:05:47
Documents
2
Period of Report
2018-03-21

Document Format Files

Seq Description Document Type Size
1 3 a3.html 3  
1 3 a3.xml 3 1514
2 EX-24 ex-24.htm EX-24 10659
  Complete submission text file 0001104659-18-020444.txt   13621
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Issuer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address
Schranz Jennifer (Reporting) CIK: 0001735382 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37558 | Film No.: 18715449